全文获取类型
收费全文 | 30900篇 |
免费 | 1577篇 |
国内免费 | 723篇 |
专业分类
耳鼻咽喉 | 327篇 |
儿科学 | 664篇 |
妇产科学 | 1158篇 |
基础医学 | 7965篇 |
口腔科学 | 705篇 |
临床医学 | 1941篇 |
内科学 | 3198篇 |
皮肤病学 | 514篇 |
神经病学 | 1777篇 |
特种医学 | 614篇 |
外科学 | 1657篇 |
综合类 | 3115篇 |
一般理论 | 1篇 |
预防医学 | 3823篇 |
眼科学 | 315篇 |
药学 | 3300篇 |
3篇 | |
中国医学 | 307篇 |
肿瘤学 | 1816篇 |
出版年
2023年 | 285篇 |
2022年 | 612篇 |
2021年 | 774篇 |
2020年 | 752篇 |
2019年 | 722篇 |
2018年 | 739篇 |
2017年 | 832篇 |
2016年 | 789篇 |
2015年 | 932篇 |
2014年 | 1720篇 |
2013年 | 1783篇 |
2012年 | 1593篇 |
2011年 | 1939篇 |
2010年 | 1496篇 |
2009年 | 1555篇 |
2008年 | 1612篇 |
2007年 | 1491篇 |
2006年 | 1321篇 |
2005年 | 1108篇 |
2004年 | 971篇 |
2003年 | 910篇 |
2002年 | 650篇 |
2001年 | 653篇 |
2000年 | 619篇 |
1999年 | 559篇 |
1998年 | 566篇 |
1997年 | 529篇 |
1996年 | 550篇 |
1995年 | 560篇 |
1994年 | 533篇 |
1993年 | 448篇 |
1992年 | 422篇 |
1991年 | 358篇 |
1990年 | 327篇 |
1989年 | 287篇 |
1988年 | 261篇 |
1987年 | 210篇 |
1986年 | 174篇 |
1985年 | 253篇 |
1984年 | 246篇 |
1983年 | 146篇 |
1982年 | 144篇 |
1981年 | 136篇 |
1980年 | 119篇 |
1979年 | 107篇 |
1978年 | 80篇 |
1977年 | 65篇 |
1976年 | 56篇 |
1974年 | 39篇 |
1973年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的:了解2011-2017年四川省三州地区卫生人力资源配置现状,为三州地区卫生人力资源的合理配置提供参考。方法:利用千人卫生人力资源拥有量指标、基尼系数和卫生人力资源密度指数(HRDI)分析卫生人力资源配置现状及其公平性。结果:三州地区千人卫生人力资源拥有量呈增长趋势;基尼系数大多超过0.4,仅护士按人口分布的基尼系数较小;卫生人力资源密度指数较小,需要量、缺乏量及缺乏比例均较大。结论:三州地区卫生人力得到一定程度改善;但配置公平性较差,尤其按地理、经济分布很不均衡;医护人员短缺,需要重点投入。 相似文献
3.
内脏利什曼病是全球被忽视的传染病之一,危害严重。而利什曼原虫-人类免疫缺陷病毒(human immunodeficiency virus,HIV)合并感染对流行地区造成的威胁更甚。利什曼原虫与HIV存在相互作用,合并感染者在临床表现、诊断及治疗方面具有一定特殊性,其病死率及复发率均高于HIV阴性的内脏利什曼病患者。本文对利什曼原虫-HIV合并感染患者的临床表现、诊断和治疗进展进行综述。 相似文献
4.
目的 分析青岛市2018年1例输入性恶性疟的死亡原因,为预防疟疾死亡病例发生提供参考。方法 访谈接诊医生及患者家属,对患者病历和流行病学调查资料进行分析。结果 患者刘某,男,35岁,青岛市城阳区人,2018年3月19日到科特迪瓦务工,7月17日回国。25日患者到韩国办事,26日下午出现发冷、发热、出汗、头痛、浑身酸痛等症状,26—27日自服退烧药无好转,28日上午到韩国某医院就诊,未明确诊断,下午出现腹泻、呕吐症状,29日下午回国,14∶59到城阳区人民医院就诊,精神萎靡,经询问患者有非洲出国史可能患疟疾,16∶30将患者转诊至疟疾治疗定点医院,17∶50到达青岛市传染病医院时患者呈深昏迷状态,医生考虑患者病情危重且该院正在改建无ICU病房,建议转至有抢救条件的综合医院抢救。19:40患者转入海慈医疗集团ICU病房,21∶00被确诊为恶性疟,因病情危重,患者于30日14∶15死于多脏器功能衰竭。结论 对于输入性疟疾,根据流行病学史、临床症状和实验室检测结果尽早明确诊断,尽早使用抗疟药治疗,是避免出现死亡病例的关键。 相似文献
5.
6.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
7.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献8.
《Vaccine》2016,34(24):2663-2670
Human metapneumovirus (HMPV) is a major cause of morbidity and mortality from acute lower respiratory tract illness, with most individuals seropositive by age five. Despite the presence of neutralizing antibodies, secondary infections are common and can be severe in young, elderly, and immunocompromised persons. Preclinical vaccine studies for HMPV have suggested a need for a balanced antibody and T cell immune response to enhance protection and avoid lung immunopathology. We infected transgenic mice expressing human HLA-A*0201 with HMPV and used ELISPOT to screen overlapping and predicted epitope peptides. We identified six novel HLA-A2 restricted CD8+ T cell (TCD8) epitopes, with M39–47 (M39) immunodominant. Tetramer staining detected M39-specific TCD8 in lungs and spleen of HMPV-immune mice. Immunization with adjuvant-formulated M39 peptide reduced lung virus titers upon challenge. Finally, we show that TCD8 from HLA-A*0201 positive humans recognize M39 by IFNγ ELISPOT and tetramer staining. These results will facilitate HMPV vaccine development and human studies. 相似文献
9.
人间充质干细胞免疫原性研究 总被引:1,自引:0,他引:1
目的探讨人间充质干细胞(hMSCs)特性及免疫原性,为进一步研究hMSCs移植特性提供实验依据。方法免疫组化方法鉴定hMSCs表面HLA-ABC、HLA-DR、CD80、CD86分子;流式细胞术检测其含量;RT-PCR检测HLA-ABC、HLA-DRmRNA基因片断;外周血淋巴细胞杀伤试验及 CCK-8比色法规察淋巴细胞增殖反应;将表达绿色荧光蛋白(GFP)的DNA复合物导入hMSCs进行大鼠脑内移植,观察hMSCs在脑内的存活情况。结果 hMSCs表面少量表达HLA-ABC分子,不表达 HLA-DR、CD80、CD86分子;有少量HLA-ABC mRNA基因片断存在,未发现HLA-DR mRNA基因片断;外周血淋巴细胞杀伤试验没有发现淋巴细胞增殖反应;大鼠脑内移植hMSCs一个月后仍可见有细胞存活。结论 hMSCs具有较弱的免疫原性。 相似文献
10.
目的研究农村城市化工业化过程中县级医院院内死亡规律. 方法回顾性总结深圳市龙岗中心医院1998-2002年间病案资料. 结果全院死亡1011人;损伤中毒占38.5%,其中机动车辆交通事故占22.1%,骨折占17.7%,颅内和体内损伤占12.8%;循环系统占20%,其中脑出血占10.5%.全院平均病死率2.03%.20~39岁占39.3%,70岁以上占13.5%,不足1个月的占9.5%. 结论在农村城市化工业化过程中,病死人口将会年轻化,各种损伤引起的死亡将成为死亡的主要因素,是医院提高疗效、降低总病死率的关键. 相似文献